Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111156 | 1.00 | MEN1 (0.46) | MEN1KMT2AS1PR5TSHRALDH1A1 | |
| SCHEMBL13127866 | 0.88 | MEN1 (0.43) | MEN1KMT2ATSHRALDH1A1L3MBTL1 | |
| SCHEMBL14948183 | 0.86 | S1PR1 (0.42) | S1PR5 | |
| SCHEMBL5119012 | 0.85 | SLC6A2 (0.43) | ALDH1A1L3MBTL1 | |
| SCHEMBL4662784 | 0.85 | SLC6A2 (0.43) | ALDH1A1L3MBTL1 | |
| SCHEMBL5119008 | 0.85 | SLC6A2 (0.43) | ALDH1A1L3MBTL1 | |
| SCHEMBL4768825 | 0.83 | TSHR (0.41) | MEN1KMT2AS1PR5TSHRALDH1A1 | |
| SCHEMBL4768832 | 0.83 | TSHR (0.41) | MEN1KMT2AS1PR5TSHRALDH1A1 | |
| SCHEMBL8207589 | 0.77 | MEN1 (0.44) | MEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL1267675 | 0.74 | MEN1 (0.68) | MEN1KMT2AALDH1A1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| WO-2007121124-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | MEN1 2302/4885KMT2A 3407/4885S1PR5 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.